- Conditions
- Magnetic Resonance Imaging
- Interventions
- Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 2 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 241–264
of 304
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Complicated Parapneumonic Effusion, Empyema, Pleural
- Interventions
- Intrapleural Saline with possible escalation to intraplerual alteplase and dornase.
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Hanover, New Hampshire
- Conditions
- Triple Negative Breast Cancer
- Interventions
- [18F]FMISO-PET with contrast-enhanced MRI
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Stroke
- Interventions
- Overground slip perturbation training
- Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Mastocytosis, Anaphylaxis
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2004
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Empyema, Pleural, Pleural Infection
- Interventions
- Saline Flush
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 5
- States / cities
- Sterling Heights, Michigan • Omaha, Nebraska • New York, New York + 2 more
- Conditions
- 714leukemia, Lymphoma
- Interventions
- Bortezomib, Everolimus
- Drug
- Lead sponsor
- Brian Hill, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Coronary Artery Disease, CAD
- Interventions
- regadenoson, Optimark®, Myocardial perfusion MRI
- Drug · Device
- Lead sponsor
- Daniel S. Berman
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hot Flushes, Vasomotor Symptoms
- Interventions
- MF101 5 g/day, Placebo, MF101 10 g/day
- Drug
- Lead sponsor
- Bionovo
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2011
- U.S. locations
- 50
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 44 more
- Conditions
- Ischemic Heart Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Rib Fractures
- Interventions
- Ropivacaine, Normal Saline Flush, 0.9% Injectable Solution
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
- Interventions
- filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Eligibility
- Up to 55 Years
- Enrollment
- 213 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2019
- U.S. locations
- 2
- States / cities
- Minneapolis, Minnesota • Seattle, Washington
- Conditions
- Complication of Urinary Catheter
- Interventions
- Ethanol Lock
- Drug
- Lead sponsor
- Children's Healthcare of Atlanta
- Other
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Ischemic Heart Disease
- Interventions
- Regadenoson
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Epidural Analgesia, Obstetric
- Interventions
- DepoDur following epidural lidocaine, DepoDur following spinal anesthetic
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Necrotizing Enterocolitis of Newborn, Bowel Ischemic
- Interventions
- Sulfur hexafluoride lipid-type A microspheres
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 0 Years to 18 Months
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Neoplasms, Bile Duct Neoplasms
- Interventions
- Oxaliplatin, Capecitabine, Sorafenib
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Hypertension
- Interventions
- clevidipine
- Drug
- Lead sponsor
- The Medicines Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Philadelphia, Pennsylvania
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
- Interventions
- fezolinetant - reference formulation, Placebo
- Drug
- Lead sponsor
- Shehzad Basaria, M.D.
- Other
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Kidney Failure, Chronic
- Interventions
- Deceased donor nephrectomy, prior to cross clamp of donor aorta, Deceased donor nephrectomy, standard of care
- Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatorenal Syndrome
- Interventions
- Terlipressin, Placebo
- Drug
- Lead sponsor
- Mallinckrodt
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 71
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 51 more
- Conditions
- Persistent Pulmonary Hypertension of the Newborn
- Interventions
- 1 dose of sildenafil
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 364 Days
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Louisville, Kentucky + 6 more
- Conditions
- Pheochromocytoma, Neuroblastoma
- Interventions
- 123I-mIBG (meta-iodobenzylguanidine)
- Drug
- Lead sponsor
- GE Healthcare
- Industry
- Eligibility
- Not listed
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Princeton, New Jersey
- Conditions
- Flushing
- Interventions
- Quercetin, Placebo
- Dietary Supplement
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania